← Back to Search

Monoclonal Antibodies

AMG 701 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 months
Awards & highlights

Study Summary

This trial is testing a new drug, AMG 701, for safety and effectiveness in treating multiple myeloma. The first part of the trial will test different doses of the drug to find the best one. The second part will test the drug in combination with another drug, pomalidomide, with and without dexamethasone.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of subjects with clinically-significant changes in clinical laboratory tests
Number of subjects with clinically-significant changes in electrocardiogram (ECG) measurements
Number of subjects with clinically-significant changes in physical examination measurements
+5 more
Secondary outcome measures
Anti-tumor activity: Best overall response of complete response (CR)
Anti-tumor activity: Best overall response of partial response (PR)
Anti-tumor activity: Best overall response of stringent complete response (sCR)
+12 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: AMG 701 + Pomalidomide + DexamethasoneExperimental Treatment3 Interventions
Group II: AMG 701 + PomalidomideExperimental Treatment2 Interventions
Group III: AMG 701Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pomalidomide
2011
Completed Phase 2
~1020
Dexamethasone
2007
Completed Phase 4
~2590

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,370 Previous Clinical Trials
1,377,514 Total Patients Enrolled
96 Trials studying Multiple Myeloma
20,566 Patients Enrolled for Multiple Myeloma
MDStudy DirectorAmgen
913 Previous Clinical Trials
923,957 Total Patients Enrolled
44 Trials studying Multiple Myeloma
11,171 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the process open for enrolling participants in this experiment?

"Reports found on clinicaltrials.gov state that the trial, first published in 2017 and last updated in 2022, is no longer accepting patients at this time. Nevertheless, there are 1,376 separate studies actively enrolling participants right now."

Answered by AI

Are there any other experiments or investigations that have utilized AMG 701?

"AMG 701 was initially tested in 2002 at Manitoba's Blood & Marrow Transplant Program. Since then, 1135 clinical trials have concluded with a further 569 presently recruiting participants – many of them located in Toronto, Ontario."

Answered by AI

What ailments is AMG 701 typically prescribed to treat?

"AMG 701 is a common treatment for ophthalmia, sympathetic. Additionally, this medication has been found to provide relief in cases of branch retinal vein occlusion and macular edema."

Answered by AI

What is the uppermost limit of participants in this clinical trial?

"This research is no longer accepting new participants. It was first published in November 2017 and recently altered on the 29th of November 2022. If you are searching for alternative studies, there are 807 trials recruiting patients with neoplasms or plasma cell disorders as well as 569 actively enrolling individuals under AMG 701's umbrella."

Answered by AI

How many sites are overseeing the implementation of this clinical trial?

"This medical trial has a total of 17 participating sites, with notable centres including University Health Network-Princess Margaret Cancer Centre in Toronto, Wake Forest Baptist Health in Winston-Salem and the University of Utah Huntsman Cancer Institute in Salt Lake City."

Answered by AI

What sort of adverse effects has AMG 701 been associated with in clinical trials?

"Due to being a Phase 1 trial, and having limited data supporting safety and efficacy, AMG 701 received a score of 1 in terms of security."

Answered by AI
Recent research and studies
Blood AdvancesJournal
The Immunomodulatory Drugs Lenalidomide and Pomalidomide Enhance the Potency of AMG 701 in Multiple Myeloma Preclinical Models
Cho, Shih-Feng, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A. Hsieh, et al.. 2020. “The Immunomodulatory Drugs Lenalidomide and Pomalidomide Enhance the Potency of AMG 701 in Multiple Myeloma Preclinical Models”. Blood Advances. American Society of Hematology. doi:10.1182/bloodadvances.2020002524.
clinicaltrials.govStudy
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
2017. "A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03287908.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top